Segment Description: Andrea L. Cox, MD, PhD, professor of medicine, Johns Hopkins University, comments on the future of HCV vaccine development efforts in light of a 2019 trial which did not prevent chronic infection.
Interview transcript (modified slightly for readability):
Cox: We'd like to learn more about the effect that the vaccine did mediate on the pathogen. We'd like to learn if there were any individuals who mounted particularly effective immune responses against the pathogen to help inform additional vaccine design. In summary, I would say that the vaccines were well tolerated and we did successfully complete a trial among people who are actively injecting drugs.
But, given the WHO [World Health Organization] target of eliminating hepatitis C by 2030, and the ongoing epidemic of acute hepatitis C virus infection in North America, we need to do more to try to interrupt transmission and prevent disease from this global pathogen.
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512